

Protalix BioTherapeutics, Inc.  
Form 8-K  
November 02, 2010

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 2, 2010 (November 2, 2010)**

**Protalix BioTherapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Florida**  
(State or other jurisdiction  
of incorporation)

**001-33357**  
(Commission File Number)

**65-0643773**  
(IRS Employer  
Identification No.)

**2 Snunit Street**  
**Science Park, POB 455**  
**Carmiel, Israel**  
(Address of principal executive offices)

**20100**  
(Zip Code)

**Registrant's telephone number, including area code +972-4-988-9488**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EX-99.1

---

**Table of Contents**

**Item 8.01. Other Events**

On November 2, 2010, Protalix BioTherapeutics, Inc. (the Company ) issued a press release announcing positive preliminary data from the first 15 patients that completed the Company s nine month, worldwide, multi-center, open-label, switch-over trial of taliglucerase alfa for the treatment of Gaucher disease. A copy of the press release is attached hereto as Exhibit 99.1

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated November 2, 2010.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: November 2, 2010

By: /s/ David Aviezer  
Name: David Aviezer, Ph.D.  
Title: President and Chief Executive  
Officer